片山 昌紀 かたやま まさき 先生

来歴等

略歴

2005年 京都大学医学部 医学科 卒業
2005年 高松赤十字病院 臨床研修医
2007年 京都大学医学部附属病院 免疫・膠原病内科 専門修練医
2008年 京都大学大学院医学研究科 博士課程（医学専攻 ＜臨床免疫学＞）
2012年 京都大学医学部附属病院 免疫・膠原病内科 医員
2013年 大阪赤十字病院 リウマチ・膠原病内科 医員
2020年 大阪赤十字病院 リウマチ・膠原病内科 医長
2022年 大阪赤十字病院 リウマチ・膠原病内科 副部長

論文

• 1. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 49: 2298-2304.

  Ohmura K, Terao C, Maruya E, Katayama M, et al. (2010)

• 2. 【関節炎の鑑別:診断と治療の進歩】 全身性硬化症・混合性結合組織病. 日本内科学会雑誌 99: 2407-2413.

  片山昌紀, 三森経世 (2010)

• 3. Myelin basic protein as a novel genetic risk factor in rheumatoid arthritis--a genome-wide study combined with immunological analyses. PLoS One 6: e20457

  Terao C, Ohmura K, Katayama M, et al. (2011)

• 4. A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Ann Rheum Dis.

  Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, et al. (2011)

• 5. ACPA-negative RA consists of two genetically distinct subsets based on RF positivity in Japanese. PLoS One 7: e40067.

  Terao C, Ohmura K, Ikari K, Kochi Y, Maruya E, Katayama M, et al. (2012)

• 6. Neutrophils are essential as a source of IL-17 in the effector phase of arthritis. PLoS One 8: e62231.

  Katayama M, Ohmura K, Yukawa N, Terao C, Hashimoto M, et al. (2013)

• 7. An association between amino acid position 74 of HLA-DRB1 and anti-citrullinated protein antibody levels in Japanese patients with anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol 67: 2038-2045.

  Terao C, Suzuki A, Ikari K, Kochi Y, Ohmura K, Katayama M, et al. (2015)

• 8. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. Jun;76(6):1051-1056.

  Fukuda W, Hanyu T, Katayama M,et al.(2017)

• 9. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. Aug 3;20(1):165

  Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, et al. (2018)

• 10. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One. Mar 15;13(3):e0194130.

  Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M,et al(2018)

• 11. Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Mod Rheumatol. Jul;28(4):626-636

  Okabe N, Ohmura K, Katayama M et al. (2018)

• 12. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther. Nov 28;21(1):255.

  Fukuda W, Hanyu T, Katayama M,et al.(2019)

• 13. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther. Apr 11;21(1):91.

  Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M et al.(2019)

• 14. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One. May 8;14(5):e0216624.

  Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M et al.(2019)

• 15. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. Mar;72(3):488-498.

  Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, Taguchi Y, Katayama M,et al.(2020)

• 16. The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. Rheumatol Int. Feb;40(2):217-225.

  Murata K, Hashimoto M, Yamamoto W, Son Y, Amuro H, Nagai K, Takeuchi T, Katayama M et al.(2020)

• 17. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatol Int. Dec;40(12):1987-1995.

  Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W, Murata K, Takeuchi T, Kotani T, Maeda Y, Ebina K, Son Y, Amuro H, Hara R, Katayama M et al.(2020)

• 18. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. Clin Rheumatol. Sep;39(9):2563-2572.

  Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Nagai K, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Katayama M et al.(2020)

• 19. Drug retention of 7 biologics and tofacitinib in biologics-na?ve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. Jun 15;22(1):142.

  Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Shiba H, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Katayama M et al.(2020)

• 20. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clin Rheumatol. Jan 29.

  Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Onishi A, Jinno S, Hara R, Son Y, Amuro H, Takeuchi T, Yoshikawa A, Katayama M et al,(2021)

• 21. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther. Apr 15;23(1):116.

  Jinno S, Onishi A, Dubreuil M, Hashimoto M, Yamamoto W, Murata K, Takeuchi T, Kotani T, Maeda Y, Ebina K, Son Y, Amuro H, Hara R, Katayama M, Saegusa J. (2021)

• 22. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study. Rheumatol Int. Jul;41(7):1233-1241.

  Maeda Y, Hirano T, Ebina K, Hara R, Hashimoto M, Yamamoto W, Murakami K, Kotani T, Hata K, Son Y, Amuro H, Onishi A, Jinno S, Katayama M, Kumanogoh A. (2021)

• 23. The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis: Findings From the ANSWER Study. Am J Kidney Dis. Nov;78(5):761-764.

  Onishi A, Akashi K, Yamamoto W, Ebina K, Murata K, Hara R, Katayama M et al. (2021)

• 24. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study. Scand J Rheumatol. Sep 13:1-10.

  Nakayama Y, Hashimoto M, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M et al.(2021)

• 25. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatol Int. 2022 Jul;42(7):1227-1234.

  Nakayama Y, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M et al,(2022)

• 26. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022 Jan 7;12(1):134.

  Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Onishi A, Jinno S, Hara R, Son Y, Amuro H, Takeuchi T, Yoshikawa A, Katayama M et al,(2022)